Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-08-28
2007-08-28
Anderson, Rebecca (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C540S578000
Reexamination Certificate
active
10515700
ABSTRACT:
The present invention relates to derivatives of 1-thia-3-aza-dibenzoazulene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-α (TNF-α) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
REFERENCES:
patent: 3711489 (1973-01-01), Lombardino
patent: 4198421 (1980-04-01), Cherkofsky et al.
patent: 967573 (1975-05-01), None
patent: 20000310 (2002-02-01), None
patent: WO-01/87890 (2001-11-01), None
Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 2050-2057.
Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 1992-1996.
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the Internet, URL; http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/indexhtml>.
Mrak, et al. Potential Inflammatory biomarkers in Alzheimer's disease. Journal of Alzheimer's Disease, 2005, 8, 369-375.
Kovtunenko, et al. Synthesis of thiazoles according to Hantzsch from 11-bromo-10, 11-dihydrodibenz[b,f] thienpin-10-ones. Ukrainskii Khimicheskii Zhurnal. 1983, 49, 975-978.
Cagniant and Kirsch, C.R. Acad. Sc. Paris, 1976, 283:683-686.
Kovtunenko et al., Ukr. Khim. Zh., 1983, 43:975-978.
Bresnihan, Treatment with Recombinant Human Interleukin-1 Receptor Antagonist (rhlL-1ra) in Rheumatoid Arthritis (RA); Results of a Randomized Double-Blind, Placebo-Controlled Multicenter trial, Arthrit. Rheum., 1996, 39:73.
Mori et al., Attenuation of Collagen-Induced Arthritis in 55-kDa TNF Receptor Type 1 (TNFR1)-IgG1-Treated and TNFR1-Deficient Mice, J. Immunol., 1996, 157:3178-3182.
Van Assche and Rutgeerts, Anti-TNF agents in Crohn's disease, Exp. Opin. Invest. Drugs, 2000, 9:103-111.
Keffer at al., Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis, EMBO J., 1991, 10:4025-4031.
Elliott et al., Randmoised double-blind comparsion of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis, The Lancet, 1994, 344:1105-1110.
Carswell et al., An endotoxin-induced serum factor that causes necrosis of tumors, Proc. Natl. Acad. Sci. U.S.A., 1975, 72:3666-3670.
Dinarello, An Update on Human Interleukin-1: From Molecular Biology to Clinical Relevance, J. Clinical Immunology, 1985, 5:287.
Georgopoulos et al., Transmembrane TNF Is Sufficient To Induce Localized Tissue Toxicity and Chronic Inflammatory Arthritis In Transgenic Mice, J. Inflamm., 1996, 46:86-97.
Dinarello, Interleukin-1, Rev. Infect Disease, 1984, 6(1):51-95.
Pfeffer et al., Mice Deficient for the 55kd Tumor Necrosis Factor Receptor Are Resistant to Endotixic Shock, yet Succumb to L. monocytogenes Infection, Cell, 1993, 73:457-467.
Teitei, The Synthesis of 2-(5-Phenylthiazol-4-yl)benzoic Acids, Aust. J. Chem., 1980, 33:605-611.
Mattioli and Ghia, omega-Dialkylaminoalkyl Ethers of Phenyl-(5-substituted 1-phenyl-1H-pyrazol-4-yl) methanols with Analgesic and Anti-inflammatory Activity, J. Heterocyclic Chem., 1997, 34:963-968.
Collier et al., The Abdominal Constriction Response and Its Suppression By Analgesic Drugs in the Mouse, Br. J. Pharmac. Chemother., 1968, 32:295-310.
Schweizer et al., Combined automated writhing/motility test for testing analgesics, Agents and Actions, 1988, 23:29-31.
Fukawa et al., A Method for Evaluating Analgesic Agents in Rats, J. Pharmacol. Meth., 1980, 4:251-259.
Badger et al., Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function, J. Pharmac. Env. Therap., 1996, 279(3):1453-1461.
Kidemet Davor
Mercep Mladen
Mesic Milan
Modric Marina
Pesic Dijana
Anderson Rebecca
GlaxoSmithKline Istrazivacki Centar Zagreb D.O.O.
Young J. Scott
Young Shawquia
LandOfFree
1-thia-3-aza-dibenzoazulenes as inhibitors of tumour... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3879143